ReviewCancers2020
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- Ivermectin, a potential anticancer drug derived from an antiparasitic drug.Pharmacological research · 2021Pooled it
- Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).Japanese journal of clinical oncology · 2022Trial
- Molecular insights into triazole-based compounds for triple-negative breast cancer treatment.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Pectolinarigenin fromPharmaceuticals (Basel, Switzerland) · 2026Article
- An Overview of Emerging Trends in Targeted Therapy of Triple-Negative Breast Cancer.International journal of breast cancer · 2026Review
- Transarterial infusion chemotherapy combined with microwave ablation for inoperable triple-negative breast cancer: a case report.Frontiers in oncology · 2026Article
- Article
- Immunotherapy in Triple-Negative Breast Cancer.Oncology and therapy · 2025Review
- Article
- Ethnobotanical survey of medicinal plants used in management of breast cancers in Qatar.Heliyon · 2025Article
- Cancer-associated fibroblasts promote doxorubicin resistance in triple-negative breast cancer through enhancing ZFP64 histone lactylation to regulate ferroptosis.Journal of translational medicine · 2025Article
- Integrated Network Pharmacology, Machine Learning and Experimental Validation to Identify the Key Targets and Compounds ofOncoTargets and therapy · 2025Article
- Analysis of single-cell and spatial transcriptomics in TNBC cell-cell interactions.Frontiers in immunology · 2025Review
- Exosomal Delivery of miR-155 Inhibitor can Suppress Migration, Invasion, and AngiogenesisCurrent medicinal chemistry · 2025Article
- Response of MDA-MB231 cells to cisplatin and paclitaxel - viability, migration and gene expression estimation in mono- and co-culture with macrophages.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Article
- An insight into the therapeutic effects of isoliquiritigenin in breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Solid Lipid Nanoparticles, an Alternative for the Treatment of Triple-Negative Breast Cancer.International journal of molecular sciences · 2024Review
- Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells.BMC medicine · 2024Article
- Prognostic Values of CD8+, PARP, and EGFR on Overall Survival in Patients with Triple-Negative Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Investigating the Immunogenic Cell Death-Dependent Subtypes and Prognostic Signature of Triple-Negative Breast Cancer.Phenomics (Cham, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence compared with other breast cancer subtypes. Anthracycline- and taxane-based chemotherapy is still the mainstay of treatment in early stages, although several escalation approaches have been evaluated to improve survival outcomes. The addition of platinum salts to standard neoadjuvant chemotherapy (NACT) remains controversial due to the lack of clear survival advantage, and the use of adjuvant capecitabine represents a valid treatment option in TNBC patients with residual disease after NACT. Recently, several clinical trials showed promising results through the use of poly ADP-ribose polymerase (PARP) inhibitors and by incorporating immunotherapy with chemotherapy, enriching treatment options beyond conventional cytotoxic agents. In this review, we provided an overview on the current standard of care and a comprehensive update of the recent advances in the management of early stage TNBC and focused on the latest emerging biomarkers and their clinical application to select the best therapeutic strategy in this hard-to-treat population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.